Urologists near Elmhurst, NY

Biography: Dr. Michael Schulster, MD is an Urology Specialist who practices in New York, NY. Dr. Michael Schulster, MD is affiliated with Newyork-Presbyterian/Columbia University Medical Center.

Biography: Dr. Luay Alshara is a triple fellowship-trained Endourologist and Robotic Surgeon, who servces as an Associate Professor of Urology at Weill Cornell Medicine and Associate Attending Urology at NewYork-Presbyterian Hospital. He brings years of expertise from his time as a faculty member at Albany Medical College, where he practiced in the New York Capital Region.Dr. Alshara completed his advanced fellowship training in Endourology at Glickman Urological and Kidney Institute at the Cleveland Clinic. He also completed extensive fellowship training in Robotic Surgery at St. Elizabeth's Medical Center Tufts University in Boston and Jackson Health System in Miami.Dr. Alshara is an expert in complex kidney stone surgeries, including various techniques for PCNL (Percutaneous Nephrolithotomy) tailored to the complexity of each patient, ECIRS (Endoscopic Combined Intrarenal Surgery), mini-PCNL, RIRS (Retrograde Intra-Renal Surgery) and robotic assisted stone removal. He also specializes in reconstructive robotic procedures for conditions like ureteral stricture disease and UPJ (ureteropelvic junction) obstruction. Dr. Alshara is an expert in management of large prostate glands, focusing on robotic-assisted prostate surgery and Holmium Laser Enucleation of the Prostate (HoLEP).Committed to advancing patient care, Dr Alshara integrates the latest technologies and techniques into his practice to improve patient outcomes and quality of life. Dr. Alshara is dedicated to offering cutting-edge, minimally invasive surgical solutions, and pioneering advanced programs for prostate laser enucleation using innovative laser technologies.Dr. Alshara has published in the fields of endourology and stone disease, with a focus on improving patient satisfaction, surgical outcomes, and cost-efficiency. Equally committed to education, he is dedicated to mentoring and training the next generation of urologists in the field.

Biography: Dr. Davuluri joined the Weill Cornell Urology team after completing her General Surgery internship and Urology residency at Albert Einstein College of Medicine - Montefiore Medical Center. She received her medical degree from SUNY Upstate Medical University in Syracuse, NY where she was inducted into the Gold Humanism Honors Society. Prior to medical school, she received her Master's in Public Health from Dartmouth College. She has published numerous papers within Urology as well as authored chapters for Urologic textbooks. She also has served as a reviewer for major urologic journals. She is passionate about disparities in healthcare and is a fellow with Weill Cornell Medicine's Department of Population Health Sciences. Dr. Davuluri's current research focuses on outcomes associated with prostate cancer treatment and improving the quality of life in prostate cancer survivors. She is an active member of the American Urologic Association, New York Section of the AUA, and the American Medical Association.

Biography: Dr. Juan Garisto is an Assistant Professor of Clinical Urology at Weill Cornell Medicine as well as an Uro-Oncologist and Robotic Surgeon within the NYP-Brooklyn Campus. Dr. Garisto completedhis Society of Urologic Oncology (SUO) fellowship at University of Toronto Princess Margaret Hospital (2015-2017). He continued his training in minimally invasive surgery at the Cleveland Clinic Foundation (2017-2020). He had the opportunity to be part of the surgical team that performed the first single port robotic urology procedure in the United States. With a practice focused on minimally invasive treatment for urologic cancers, Dr. Garisto is the author of over 100 peer reviewed publications and several surgical book chapters. Dr. Garisto's research focuses on active surveillance for prostate cancer, orthotopic bladder cancer models, and adjuvant immunotherapy for urologic malignancies. Dr. Garisto will be seeing patients at the NYP-Brooklyn Campus and is taking on the role of NYP- Brooklyn Site Director for Urologic Oncology.

Biography: Dr. Bashir Al Hussein is a Urologic Oncologist and Assistant Professor of Urology at Weill Cornell Medicine. He received his Medical Degree from the University of Jordan School of Medicine in Amman, Jordan, his hometown. He completed his Urology residency at NewYork-Presbyterian /Weill Cornell Medical Center, followed by a Society of Urologic Oncology fellowship at Vanderbilt University Medical Center. Additionally, he earned a Master of Public Health, with a concentration in Epidemiology, from Vanderbilt University School of Medicine.Dr. Al Hussein's research interests include applying epidemiological methods to improve care quality for cancer patients, focusing on decision-making, survivorship, and disparities stemming from social determinants of health. His work has led to publications in journals such as the Journal of the American Medical Association (JAMA), the New England Journal of Medicine, and JAMA Internal Medicine. He also is a recipient of the American Urological Association Research Scholar Award.In his clinical practice, Dr. Al Hussein is committed to providing patient-centered care, leveraging both robotic and traditional open surgical approaches to effectively manage genitourinary cancers.NewsMost Men With Low-Risk Prostate Cancers Now Forgo Immediate Surgeryhttps://www.usnews.com/news/health-news/articles/2023-04-04/most-men-with-low-risk-prostate-cancers-now-forgo-immediate-surgeryDecade-Long Study Offers Guidance on Treatments for Prostate Cancerhttps://www.usnews.com/news/health-news/articles/2024-01-24/decade-long-study-offers-guidance-on-treatments-for-prostate-cancerInsights into adverse effects may help guide prostate cancer treatment decision-makinghttps://www.healio.com/news/hematology-oncology/20240227/insights-into-adverse-effects-may-help-guide-prostate-cancer-treatment-decisionmakingComparing Side Effects of Prostate Cancer Treatmentshttps://newsinhealth.nih.gov/2024/04/comparing-side-effects-prostate-cancer-treatmentsMore U.S. Prostate Cancer Patients Choosing Active Surveillancehttps://www.newswise.com/articles/more-u-s-prostate-cancer-patients-choosing-active-surveillance2More Men Choose Active Surveillance for Prostate Cancerhttps://www.newsmax.com/health/health-news/prostate-cancer-low-risk/2023/04/05/id/1115105/More men with prostate cancer opting for active surveillancehttps://www.healio.com/news/hematology-oncology/20230403/more-men-with-prostate-cancer-opting-for-active-surveillancehttps://www.usatoday.com/story/news/health/2024/01/24/prostate-cancer-treatment-study/72336323007/10-year study evaluates prostate cancer treatments, side effectshttps://www.msn.com/en-us/health/other/10-year-study-evaluates-prostate-cancer-treatments-side-effects/ar-BB1hc5v7Understanding Functional Outcomes in Prostate Cancerhttps://www.medscape.com/s/viewarticle/understanding-functional-outcomes-prostate-cancer-2024a10001t2?src=rssTreatment Adverse Events Vary With Favorable, Unfavorable Prognosis in Prostate Cancerhttps://www.physiciansweekly.com/treatment-adverse-events-vary-with-favorable-unfavorable-prognosis-in-prostate-cancer/

Care Philosophy: After developing an interest in fighting cancer in medical school, I was fortunate to work with and learn from leadersin the field of genitourinary oncology during internship, residency, and fellowship training. I feel fortunate to have joined the faculty at Weill Cornell to work with renowned mentors and colleagues in both medical oncology and urology. Together I am confident we will make progress towards increasing the cure rate and decreasing suffering from these diseases.

Biography: Dr. Cora Sternberg is a leading international researcher and world expert in the field of medical oncology, genitourinary (GU) cancers, and drug development. As a key opinion leader in three different types of genitourinary cancers, Dr. Sternberg isknown for her influential work in developing novel therapies and targeted agents for the treatment of prostate, renal and bladder cancers.Dr. Sternberg helped develop the original M-VAC chemotherapy regimen, as well as the double-dose/high-dose/accelerated-dose M-VAC chemotherapy regimens in bladder and urothelial cancers. These treatments are the gold standard, saving many lives and decreasing suffering in patientswith these diseases.Additionally, Dr. Sternberg has served as principal investigator or been involved in numerous practice-changing studies for prostate cancer. These research efforts have led to the FDA approvals of abiraterone acetate and enzalutamide in advanced prostate cancer. Most recently, her publication in the New England Journal of Medicine (NEJM) demonstrated dramatic improvements in metastasis-free survival (MFS) in men with castration resistant prostate cancer (CRPC) without evidence of metastatic disease, but at high risk of developing metastases, a population for whom there were previously no approved therapeutics. This research led to the approval of enzalutamide in the M0 CRPC patient population.Dr. Sternberg has been instrumental in the development of the drug Pazopanib, an antiangiogenic targeted therapy, for advanced clear cell renal cell carcinoma. Dr. Sternberg served as lead investigator in the large phase 3 international study that demonstrated the efficacy, safety and tolerability of this drug in patients with metastatic kidney cancer, culminating in the FDA approval. She has also participated in the development of other antiagiogenic agents such as sunitinib, cabozantinib, tivozanib and dovitinib to treat renal cell cancer.At Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Sternberg will facilitate the continued growth and development of clinical and translational research programs in genitourinary (GU) malignancies, with a particular emphasis on expanding the breadth and depth of clinical and translational research. AsClinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens. In addition to providing her clinical and research expertise in genitourinary oncology, Dr. Sternberg will work closely with Olivier Elemento, PhD, renowned computational biologist and Director of the EIPM, to develop novel strategies and apply precision oncology to optimize cancer prevention, detection and treatment across a variety of tumor types.Dr. Sternberg previously served as Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy, and adjunct Professor of Oncology at La Sapienza University in Rome. A graduate of the University of Pennsylvania undergraduate and medical schools, Dr. Sternberg completed her fellowship and previously was on staff at Memorial Sloan Kettering Cancer Center.Dr. Sternberg has published approximately 400 articles in peer-reviewed publications,including more than 100 first-authored articles. She has co-edited six textbooks, guest edited six others, and has published over 80 book chapters. Dr. Sternberg has lectured extensively at universities and cancer symposia worldwide, having given approximately 750 invited talks atprestigious international venues.Throughout her career, she has served on the editorial boards of Critical Reviews in Hematology and Oncology, Annals of Oncology, and the Journal of Clinical Oncology, and she currently serves on the editorial boards of Oncology, European Urology, the Harvard Medical School Annual Report on Prostate Diseases, Kidney Cancer, Nature Clinical Practice Urology, and European Urology Oncology. Dr. Sternberg also serves as Reviewer for the New England Journal of Medicine, the Journal of Clinical Oncology, the Lancet Oncology and others.She currently serves as the Solid Tumor Editor for Critical Reviews in Hematology and Oncology, Section Editor for Urologic Oncology, Associate Editor for Bladder Cancer Clinical Trials Corner, Associate Editor and Genitourinary Oncology Editor for ESMO Open-Cancer Horizons, and Associate Editor for Frontiers in Oncology. Additionally, Dr. Sternberg previously served as Oncology Editor for the British Journal of Urology, Section Editor for Urologic Oncology, and Genitourinary Editor for the European Journal of Cancer.Dr. Sternberg's leadership in the field is further exemplified by the numerous international committees on which she has served. She was elected to three consecutive terms as Board Member and Executive Board Member of the European Organization for Research and Treatment of Cancer (EORTC) and elected to the nominating committee of the American Society of Clinical Oncology (ASCO) board of directors, currently serving a 3-year term.This document has been edited with the instant web content composer which can be found at htmleditor.tools - give it a try.